BR112019002655A2 - composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora - Google Patents

composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora

Info

Publication number
BR112019002655A2
BR112019002655A2 BR112019002655A BR112019002655A BR112019002655A2 BR 112019002655 A2 BR112019002655 A2 BR 112019002655A2 BR 112019002655 A BR112019002655 A BR 112019002655A BR 112019002655 A BR112019002655 A BR 112019002655A BR 112019002655 A2 BR112019002655 A2 BR 112019002655A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
composition
surprising
neuromodulatory
Prior art date
Application number
BR112019002655A
Other languages
English (en)
Inventor
Sterman Heimann Andrea
Amaral Remer Ricardo
Original Assignee
Proteimax Biotecnologia Ltda
Remer Consultores Assessoria Empresarial Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/BR2017/050314 external-priority patent/WO2018068120A1/pt
Application filed by Proteimax Biotecnologia Ltda, Remer Consultores Assessoria Empresarial Ltda filed Critical Proteimax Biotecnologia Ltda
Publication of BR112019002655A2 publication Critical patent/BR112019002655A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)

Abstract

a presente invenção situa-se nos campos da farmácia, medicina, química e biotecnologia. o composto da presente invenção é peptídico mostrou surpreendente estabilidade e facilidade de manipulação quando comparado aos compostos peptídicos mais assemelhados. a composição farmacêutica da invenção compreende o referido composto peptídico e mostrou surpreendentes resultados terapêuticos mesmo quando administrada por via oral. em algumas concretizações, a administração da composição da invenção proporcionou superiores resultados terapêuticos quando comparada aos efeitos da hemopressina e do canabidiol. em algumas concretizações, a administração oral da composição da invenção proporciona importantes e surpreendentes resultados de neuromodulação, tanto no tratamento curativo ou profilático de convulsões, da modulação do limiar da dor e importante neuroproteção, tendo também reduzido substancialmente os sintomas clínicos da esclerose múltipla.
BR112019002655A 2017-05-15 2018-05-14 composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora BR112019002655A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102017010169-0A BR102017010169A2 (pt) 2017-05-15 2017-05-15 composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante
PCT/BR2017/050314 WO2018068120A1 (pt) 2016-10-13 2017-10-11 Uso de composto, intermediário de síntese, composição farmacêutica e método terapêutico neuromodulador
PCT/BR2018/050156 WO2018209415A1 (pt) 2017-05-15 2018-05-14 Composto, intermediário de síntese, uso, composição farmacêutica e método terapêutico neuromodulador

Publications (1)

Publication Number Publication Date
BR112019002655A2 true BR112019002655A2 (pt) 2019-07-02

Family

ID=64273083

Family Applications (2)

Application Number Title Priority Date Filing Date
BR102017010169-0A BR102017010169A2 (pt) 2016-10-13 2017-05-15 composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante
BR112019002655A BR112019002655A2 (pt) 2017-05-15 2018-05-14 composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR102017010169-0A BR102017010169A2 (pt) 2016-10-13 2017-05-15 composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante

Country Status (6)

Country Link
US (1) US20220098237A1 (pt)
EP (1) EP3626727A4 (pt)
JP (1) JP7241032B2 (pt)
CN (1) CN110891963B (pt)
BR (2) BR102017010169A2 (pt)
WO (1) WO2018209415A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016023848A2 (pt) * 2016-10-13 2018-05-02 Proteimax Biotecnologia Ltda Anticonvulsivante, uso e composição farmacêutica contendo o mesmo
WO2020154679A1 (en) * 2019-01-25 2020-07-30 The Board Of Regents Of The University Of Texas System Novel non-opioid anti-pain medication
EP4282425A1 (en) 2021-01-19 2023-11-29 Proteimax Biotecnologia Ltda Use of compound, pharmaceutical composition for the treatment of immune or metabolic disorders, pharmaceutical composition for the treatment of illnesses caused by or associated with viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888794A (en) * 1990-07-11 1999-03-30 New York University Receptor-type phosphotyrosine phosphatase-alpha
EP1608947A4 (en) * 2002-10-02 2009-06-17 Catalyst Biosciences Inc PROCESS FOR PRODUCING AND TESTING FOR PROTEASES WITH CHANGED SPECIFICITY
US20040258695A1 (en) * 2003-01-31 2004-12-23 Schryvers Anthony Bernard Transferrin binding peptides and uses thereof
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
CA2657328A1 (en) * 2006-07-08 2008-01-17 University Of Kentucky Research Foundation Lung cancer diagnostic assay
US20080146510A1 (en) * 2006-10-27 2008-06-19 Wai Ming Wong Biologically active peptide vapeehptllteaplnpk derivatives
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
AU2011256290B2 (en) * 2010-05-17 2014-06-12 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
JP5872673B2 (ja) * 2011-03-28 2016-03-01 エス．アイ．エス． シュロブ イノベイティブ サイエンス リミテッド 皮膚疾患を治療するための方法
GB201113596D0 (en) 2011-08-08 2011-09-21 Univ De Coimbra Compounds, compositions and methods to promote oligodendrogenesis and remyelination
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
BR102012017421A2 (pt) 2012-07-13 2015-04-14 Proteimax Biotecnolgia Ltda Peptídeo, composicão farmacêutica, ligante de receptor cb, metodo para modular a funcao de receptor cb, uso, método para o tratamento de obesidade, e, método para promover a redução de peso estetica em um indivíduo
EP2792684A1 (en) * 2013-04-15 2014-10-22 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions
CN104211769B (zh) * 2013-05-30 2018-08-03 中国科学院过程工程研究所 一种小分子抗体亲和肽及其应用
WO2018068120A1 (pt) * 2016-10-13 2018-04-19 Proteimax Biotecnologia Ltda Uso de composto, intermediário de síntese, composição farmacêutica e método terapêutico neuromodulador
BR102016023848A2 (pt) * 2016-10-13 2018-05-02 Proteimax Biotecnologia Ltda Anticonvulsivante, uso e composição farmacêutica contendo o mesmo

Also Published As

Publication number Publication date
JP7241032B2 (ja) 2023-03-16
US20220098237A1 (en) 2022-03-31
WO2018209415A1 (pt) 2018-11-22
EP3626727A4 (en) 2021-02-24
EP3626727A1 (en) 2020-03-25
CN110891963A (zh) 2020-03-17
CN110891963B (zh) 2024-02-20
JP2020520941A (ja) 2020-07-16
BR102017010169A2 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
ES2311756T3 (es) Administracion de la capsiacina.
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
CL2018001371A1 (es) Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807)
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112019002655A2 (pt) composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112015018168A2 (pt) inibidores de rock suaves
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2017160178A5 (pt)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
BRPI0411079A (pt) composições farmacêuticas compreendendo atorvastatina, fabricadas sem granulação
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2021000456A (es) Compuesto triciclico fusionado como inhibidor dual pde3/pde4.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
CY1124236T1 (el) Διαλυμα εγχυσης λεβοντοπα
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
JP2016528171A5 (pt)
Bali et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MY193963A (en) Composition for treating joint diseases and kit containing same
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]